Dr. Joseph Krueger, Flagship Bioscience’s Chief Scientific Officer, was recently interviewed by BioCentury about cTA™ harmonization or the potential to use one predictive assay to calibrate the output from multiple assays. Dr. Krueger provided insight about how the cTA™ platform could not only calibrate results across multiple assays, but can optimize cutoff points for patient selection. “The potential to more accurately predict which patients will respond to therapy should allow diagnostics using cTA™ to command a better price, and reimbursement, than existing companion diagnostics that require manual assessment by a pathologist.”
Read the full article here:
Data on these developments will be presented at the American Association for Cancer Research (AACR) meeting in April.
For more information on Flagship’s presentations at the meeting, read more at BioSpace.